Abstract:NOD-like receptor (NLR), family pyrin domain containing 3 (NLRP3) assembles a protein complex known as the NLRP3 inflammasome upon sensing certain pathogen products or sterile danger signals. Gain-of-function mutations such as the D301N substitution in NLRP3, which cause its constitutive activation (NLRP3CA) also results in inflammasome assembly. This inflammasome processes pro–interleukin-1 β (pro–IL-1β) and pro–IL-18 into bioactive IL-1β and IL-18, respectively, and cleaves gasdermin D (GSDMD). GSDMD amino-terminal fragments form plasma membrane pores that facilitate the secretion of IL-1β and IL-18 and lead to the inflammatory cell death pyroptosis. Accordingly, GSDMD inactivation results in negligible spontaneous inflammation in various experimental models such as in Nlrp3CA/+ mice lacking GSDMD (Nlrp3CA/+;Gsdmd−/− mice). Here, we found that Nlrp3CA/+;Gsdmd−/− mice, when challenged with LPS or TNF-α, still secreted IL-1β and IL-18, indicating inflammasome activation independent of GSDMD. Accordingly, Gsdmd−/− macrophages failed to secrete IL-1β and undergo pyroptosis when briefly exposed to NLRP3 inflammasome activators but released these cytokines when persistently activated. Sustained NLRP3 inflammasome induced caspase-8/-3 and GSDME cleavage and IL-1β maturation in vitro in Gsdmd−/− macrophages. Thus, a salvage inflammatory pathway involving caspase-8/-3–GSDME was activated after NLRP3 activation when the canonical NLRP3-GSDMD signaling was blocked. Consistent with genetic data, the active metabolite of FDA-approved disulfiram CuET, which inhibited GSDMD and GSDME cleavage in macrophages, reduced the severe inflammation and tissue damage that occurred in the Nlrp3CA/+ mice. Thus, NLRP3 inflammasome activation overwhelms the protection afforded by GSDMD deficiency, rewiring signaling cascades through mechanisms that include GSDME to propagate inflammation.

GSK3β mediates the spatiotemporal dynamics of NLRP3 inflammasome activation

NLRP3 inflammasome activation and cell death

AA467197 Controls the Hyperactivation of the NLRP3 Inflammasome During Infection

AKT Controls NLRP3 Inflammasome Activation by Inducing DDX3X Phosphorylation

The NLRP3 inflammasome: activation and regulation

Protein kinase D at the Golgi controls NLRP3 inflammasome activation

Biphasic JNK signaling reveals distinct MAP3K complexes licensing inflammasome formation and pyroptosis

The NLRP3 inflammasome: molecular activation and regulation to therapeutics

IKKβ binds NLRP3 providing a shortcut to inflammasome activation for rapid immune responses

NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain

NLRP3 Inflammasome Activation Triggers Gasdermin D–independent Inflammation

Consecutive palmitoylation and phosphorylation orchestrates NLRP3 membrane trafficking and inflammasome activation

How location and cellular signaling combine to activate the NLRP3 inflammasome

NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation

The transcriptomic landscape of canonical activation of NLRP3 inflammasome from bone marrow-derived macrophages

NLRP3 Phosphorylation is an Essential Priming Event for Inflammasome Activation.

NLRP3 inflammasome activation, metabolic danger signals, and protein binding partners

Regulation of the NLRP3 inflammasome by autophagy and mitophagy

Regulation of NLRP3 Inflammasome by Phosphorylation

ZBP1 Drives IAV-Induced NLRP3 Inflammasome Activation and Lytic Cell Death, PANoptosis, Independent of the Necroptosis Executioner MLKL

Integrated NLRP3, AIM2, NLRC4, Pyrin inflammasome activation and assembly drive PANoptosis